Christian Kim, MD
Endocrinology, Diabetes & Metabolism · Fort Lee, NJNPI 1457580177
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 1,444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,444 payments — averaging $14.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Mannkind Corporation$2K
- Corcept Therapeutics$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$2K
- plus $8K from 41 others
What the payments were for
- Food & beverage$20,16999%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$504
- JARDIANCE$498
- FARXIGA$412
- EVENITY$354
- SOLIQUA 100/33$267
- MOUNJARO$250
- Ozempic$244
- Minimed 670G System$243
- Pogo Automatic Blood Glucose Monitoring System$231
- ESPRIT$149
- KRYSTEXXA$131
- DALVANCE$125
- EYLEA$125
- ETERNA$125
- TEPEZZA$125
- Korlym$124
- Tymlos$122
- Repatha$122
- Prolia$122
- OMNI(R) SURGICAL SYSTEM (US)$121
How this compares
$20,289 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Synjardy XrEmpagliflozin/Metformin Hcl | 174 | $145,634 |
| ProliaDenosumab | 89 | $141,099 |
| OzempicSemaglutide | 98 | $121,710 |
| MounjaroTirzepatide | 98 | $112,544 |
| JardianceEmpagliflozin | 90 | $91,298 |
| TrulicityDulaglutide | 64 | $77,572 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 20 | $57,547 |
| JanuviaSitagliptin Phosphate | 49 | $43,181 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 40 | $41,898 |
| Xigduo XrDapaglifloz Propaned/Metformin | 39 | $34,921 |
| TradjentaLinagliptin | 46 | $32,083 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $31,788 |
| FarxigaDapagliflozin Propanediol | 34 | $31,322 |
| RybelsusSemaglutide | 24 | $29,522 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $20,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Synjardy, Jentadueto Xr | $916 | $292,833342 claims |
| AmgenProlia, Evenity (2 Syringes) | $2,285 | $198,646109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,944 | $190,115162 claims |
| Novo NordiskOzempic, Rybelsus | $2,083 | $151,231122 claims |
| MerckJanuvia, Janumet Xr, Janumet | $210 | $100,568106 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,592 | $31,78835 claims |
| AstraZenecaFarxiga | $999 | $31,32234 claims |
| BayerKerendia | $941 | $16,73821 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $735 | $4,019350 claims |
| AbbVieSynthroid | $178 | $2,55621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Fort Lee
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.